Press releases
- Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
- Newron Presents 2023 Financial Results and Provides 2024 Outlook
- Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Key statistics
On Friday, Newron Pharmaceuticals SpA (NP5:DUS) closed at 7.34, 93.16% above the 52 week low of 3.80 set on Jun 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.97 |
---|---|
High | 7.34 |
Low | 6.97 |
Bid | 7.22 |
Offer | 7.48 |
Previous close | 6.81 |
Average volume | 699.40 |
---|---|
Shares outstanding | 18.63m |
Free float | 17.07m |
P/E (TTM) | -- |
Market cap | 135.48m CHF |
EPS (TTM) | -0.8886 CHF |
Data delayed at least 15 minutes, as of Apr 26 2024 15:31 BST.
More ▼